357 related articles for article (PubMed ID: 22909285)
1. Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.
Rossi G; Frediani S; Rossi R; Rossi A
BMC Psychiatry; 2012 Aug; 12():122. PubMed ID: 22909285
[TBL] [Abstract][Full Text] [Related]
2. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.
Kane JM; McEvoy JP; Correll CU; Llorca PM
CNS Drugs; 2021 Nov; 35(11):1189-1205. PubMed ID: 34636025
[TBL] [Abstract][Full Text] [Related]
3. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence.
Correll CU; Citrome L; Haddad PM; Lauriello J; Olfson M; Calloway SM; Kane JM
J Clin Psychiatry; 2016; 77(suppl 3):1-24. PubMed ID: 27732772
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
5. In-Hospital Use of Long-Acting Injectable Antipsychotics and Readmission Risk in Patients With First-Admission Schizophrenia in Taiwan.
Chen W; Wu CS; Liu CC; Kuo PH; Chan HY; Lin YH; Chung YE; Chen WJ
JAMA Netw Open; 2024 Jun; 7(6):e2417006. PubMed ID: 38884998
[TBL] [Abstract][Full Text] [Related]
6. Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia.
Lafeuille MH; Dean J; Carter V; Duh MS; Fastenau J; Dirani R; Lefebvre P
Curr Med Res Opin; 2014 Aug; 30(8):1643-55. PubMed ID: 24730586
[TBL] [Abstract][Full Text] [Related]
7. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies.
Haddad PM; Taylor M; Niaz OS
Br J Psychiatry Suppl; 2009 Nov; 52():S20-8. PubMed ID: 19880913
[TBL] [Abstract][Full Text] [Related]
8. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
9. Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics.
Lin CH; Chen FC; Chan HY; Hsu CC
Int J Neuropsychopharmacol; 2019 Sep; 22(9):541-547. PubMed ID: 31260538
[TBL] [Abstract][Full Text] [Related]
10. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
[TBL] [Abstract][Full Text] [Related]
11. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia.
Potkin S; Bera R; Zubek D; Lau G
BMC Psychiatry; 2013 Oct; 13():261. PubMed ID: 24131801
[TBL] [Abstract][Full Text] [Related]
12. Long-acting injectable antipsychotics: evidence of effectiveness and use.
Manchanda R; Chue P; Malla A; Tibbo P; Roy MA; Williams R; Iyer S; Lutgens D; Banks N
Can J Psychiatry; 2013 May; 58(5 Suppl 1):5S-13S. PubMed ID: 23945067
[TBL] [Abstract][Full Text] [Related]
13. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.
Stevens GL; Dawson G; Zummo J
Early Interv Psychiatry; 2016 Oct; 10(5):365-77. PubMed ID: 26403538
[TBL] [Abstract][Full Text] [Related]
14. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.
Kishimoto T; Nitta M; Borenstein M; Kane JM; Correll CU
J Clin Psychiatry; 2013 Oct; 74(10):957-65. PubMed ID: 24229745
[TBL] [Abstract][Full Text] [Related]
15. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
16. Clinical guideline recommendations for antipsychotic long-acting injections.
Kane JM; Garcia-Ribera C
Br J Psychiatry Suppl; 2009 Nov; 52():S63-7. PubMed ID: 19880920
[TBL] [Abstract][Full Text] [Related]
17. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives.
Iyer S; Banks N; Roy MA; Tibbo P; Williams R; Manchanda R; Chue P; Malla A
Can J Psychiatry; 2013 May; 58(5 Suppl 1):14S-22S. PubMed ID: 23945063
[TBL] [Abstract][Full Text] [Related]
18. Attitude and influencing factors of patients with schizophrenia toward long-acting injections: A community-based cross-sectional investigation in China.
Sun Y; Tong J; Feng Y; Fang H; Jiang T; Zhao L; Wang Q; Yang Y
Front Public Health; 2022; 10():951544. PubMed ID: 36299738
[TBL] [Abstract][Full Text] [Related]
19. Current and emerging long-acting antipsychotics for the treatment of schizophrenia.
de Filippis R; De Fazio P; Gaetano R; Steardo L; Cedro C; Bruno A; Zoccali RA; Muscatello MRA
Expert Opin Drug Saf; 2021 Jul; 20(7):771-790. PubMed ID: 33775184
[No Abstract] [Full Text] [Related]
20. Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies.
Kishimoto T; Hagi K; Nitta M; Leucht S; Olfson M; Kane JM; Correll CU
Schizophr Bull; 2018 Apr; 44(3):603-619. PubMed ID: 29868849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
